K. Ober

Mutations in ALK signaling pathways conferring resistance to ALK inhibitor treatment lead to collateral vulnerabilities in neuroblastoma cells

M. Fischer, N. Blüthgen, M. Hubank, 2022, Molecular cancer.

Implementation of paediatric precision oncology into clinical practice: The Individualized Therapies for Children with cancer program ‘iTHER’

David C. Jones, P. Kemmeren, F. Holstege, 2022, European journal of cancer.

αβ-T Cells Engineered to Express γδ-T Cell Receptors Can Kill Neuroblastoma Organoids Independent of MHC-I Expression

Annelisa M Cornel, M. V. van Loenen, A. Bisso, 2021, Journal of personalized medicine.

Chromosome 11q loss and MYCN amplification demonstrate synthetic lethality with checkpoint kinase 1 inhibition in neuroblastoma

B. Ylstra, L. Looijenga, J. Molenaar, 2022, Frontiers in Oncology.

Neuroblastoma and DIPG Organoid Coculture System for Personalized Assessment of Novel Anticancer Immunotherapies

J. Molenaar, J. Wienke, D. V. van Vuurden, 2021, Journal of personalized medicine.

Loss of p16INK4a in neuroblastoma cells induces shift to an immature state with mesenchymal characteristics and increases sensitivity to EGFR inhibitors

F. Westermann, J. Molenaar, U. Toprak, 2021, bioRxiv.

The potential of PARP as a therapeutic target across pediatric solid malignancies

K. Ober, Marcel Kool, Natalie Jäger, 2023, BMC Cancer.